glp 1 fda approval Approves First-Of-Its-Kind Oral GLP-1 For Weight Loss FDA Approves Foundayo for Chronic

It may affect the liver enzymes responsible for drug metabolism (cytochrome P450 system), potentially altering the effectiveness or side effects of drugs like blood thinners (e.g., warfarin), anti-diabetic medications, statins, and some psychiatric drugs

However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist

BPC-157 benefits from injection near the target area for maximum localized concentration, though it also provides some systemic benefits when injected remotely

Multiple treatment options exist, including behavioural interventions, oral medications, intravesical instillations and procedures such as hydrodistension

[DOI] [PubMed] [Google Scholar] 177.Morelli L, Cappelluti MA, Ricotti L, Lenardi C, Gerges I